Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis
Sign Up to like & getrecommendations! Published in 2021 at "CNS Drugs"
DOI: 10.1007/s40263-021-00798-w
Abstract: Fingolimod (Gilenya) received regulatory approval from the US FDA in 2010 as the first-in-class sphingosine 1-phosphate (S1P) receptor (S1PR) modulator and was the first oral disease-modifying therapy (DMT) used for the treatment of the relapsing… read more here.
Keywords: treatment; sphingosine phosphate; multiple sclerosis; receptor ... See more keywords